PRESS RELEASE Paris

Sanofi delivers Business EPS(1) growth of 7.3% at CER in 2014

Good sales performance across our various businesses in 2014

Group sales(2) up 4.9% (+2.5% on a reported basis) to 33,770 million

Growth platforms(3) increased 10.7% to 25,802 million

Pharmaceuticals segment grew 4.4%, driven by Diabetes and Genzyme

Vaccines increased 7.2% and Animal Health grew 6.7%

Emerging markets(4) sales delivered 9.3% growth

Solid financial results in 2014

Business net income(1) grew 6.7% at CER to 6,847 million (+2.4% on a reported basis)

Business EPS(1) increased 7.3% at CER to 5.20

Free Cash Flow increased 12.3%

Board proposes dividend of 2.85, the 21st consecutive year of dividend growth

Recent progress on multiple new product launches

Praluent filings for the treatment of hypercholesterolemia accepted by the FDA and EMA

Dengue vaccine rolling submission initiated in several endemic countries in Asia

Lemtrada approved in the U.S. for the treatment of patients with relapsing forms of multiple sclerosis

Cerdelga , the only oral therapy for adult Gaucher disease type 1 patients, approved in the EU

Afrezza , a new rapid-acting inhaled insulin, launched in the U.S.

New advances in our R&D pipeline

Revusiran, for the treatment of familial amyloidotic cardiomyopathy, entered Phase III development

Dupilumab granted Breakthrough Therapy designation by the FDA in atopic dermatitis; Phase II study in eosinophilic oesophagitis is being initiated

2015 financial guidance

Taking into account the outlook for U.S. Diabetes as well as new product launches and late stage pipeline development, 2015 Business EPS(1) is expected to be stable to slightly growing versus 2014 at constant average exchange rates, barring major unforeseen adverse events(5)

Applying December 31, 2014 exchange rates to this full-year 2015 guidance, the additional positive currency impact on 2015 business EPS is estimated to be between 4% and 5%.

Sanofi Chairman and Chief Executive Officer, Serge Weinberg commented:

We are pleased with our solid performance in 2014. The Group delivered strong financial results and we made significant progress in bringing new medicines to market. In 2015, our focus is on operational excellence as we launch multiple new medicines and vaccines. We will also invest in our R&D projects to maximize their potential. The combination of our innovative pipeline and sustainable, diversified businesses provides a strong foundation to create long-term shareholder value.

(1) See Appendix 10 for definitions of financial indicators; (2) Growth in net sales is expressed at constant exchange rates (CER) unless otherwise indicated (see Appendix 10 for a definition); (3) See page 2; (4) See page 7 ; (5) 2014 business EPS was 5.20

Investor Relations: (+) 33 1 53 77 45 45 - E-mail: IR@sanofi.com - Media Relations: (+) 33 1 53 77 46 46 - E-mail: MR@sanofi.com

Web site: www.sanofi.com Mobile app : SANOFI IR available on the App Store and Google Play

2014 fourth-quarter and full-year figures

In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income(1) is a non-GAAP financial measure. The consolidated income statement for 2014 is provided in Appendix 4 and a reconciliation of business net income to consolidated net income in Appendix 3. Consolidated net income for 2014 was 4,390 million compared to 3,716 million for 2013. Consolidated EPS for 2014 was 3.34 versus 2.81 for 2013. Consolidated EPS for Q4 2014 was 1.02 versus 0.80 for Q4 2013.

2014 fourth-quarter and full-year sales

Unless otherwise indicated, all sales growth figures in this press release are stated at constant exchange rates(1).

In the fourth quarter of 2014, Sanofi generated sales of 9,072 million, an increase of 7.3% on a reported basis. Exchange rate movements had a positive effect of 2.7 percentage points mainly reflecting the strength of the dollar. Full-year sales reached 33,770 million, an increase of 2.5% on a reported basis. Exchange rate movements had an unfavorable effect of 2.4 percentage points reflecting the strength of the euro versus other currencies, in particular the Japanese Yen, Russian Ruble, Brazilian Real and Argentine Peso.

In the fourth quarter, sales of the Group s growth platforms increased 10.3% to 7,001 million, driven by the performance of Diabetes (up 11.0%), Vaccines (up 16.2%), Genzyme (up 22.2%) and Animal Health (up 11.5%). The Group s growth platforms accounted for 77.2% of total consolidated sales in the fourth quarter, up from 72.9% in the fourth quarter of 2013. Full-year sales of growth platforms were 25,802 million, an increase of 10.7%, and accounted for 76.4% of total consolidated sales compared with 72.5% in 2013.

(a) Includes product launches since 2009 which do not belong to the other Growth Platforms listed above: Multaq , Jevtana , Zaltrap , Auvi-Q and Mozobil .

(b) World excluding the U.S. and Canada, Western Europe, Japan, Australia and New Zealand.

(c) Excluding generics in Brazil, sales in Emerging Markets grew 6.5% in 2014.

In the fourth quarter, sales for the Pharmaceuticals business increased 2.6% to 7,388 million, driven by the U.S. and Emerging Markets. Full-year sales for Pharmaceuticals grew 4.4% to 27,720 million.

(1) See Appendix 10 for definitions of financial indicators.

(1) See Appendix 10 for definitions of financial indicators.

In the fourth quarter, sales of the Diabetes division increased 11.0% to 2,024 million driven by double-digit growth of Lantus in the U.S., Emerging Markets and Western Europe. Full-year sales of the Diabetes division grew 12.1% to 7,273 million.

In the fourth quarter Lantus sales increased 10.8% to 1,772 million. In the U.S., Lantus grew by +10.1% to 1,197m in the fourth quarter, supported by an increase of Wholesale Acquisition Cost in early November. In the U.S., Lantus SoloSTAR represented 61.7% of total Lantus sales, versus 58.0% for the same period in 2013. Lantus fourth-quarter sales were up 11.3% to 228 million in Western Europe driven by Germany, France and Italy. In Emerging Markets, Lantus sales recorded a strong performance with sales up 17.1% to 270 million in the fourth quarter, reflecting good performance in Russia, China, Turkey and Middle East. Full-year sales of Lantus reached 6,344 million, up 12.1%, reflecting a price effect of 7.3% (essentially in the U.S.) and a volume effect of 4.8%.

Amaryl sales were 91 million in the fourth quarter, down 1.1% with an increase of 6.1% to 73 million in Emerging Markets. Full-year sales of Amaryl were stable at 360 million.

Fourth-quarter sales of Apidra increased 16.0% to 96 million: the product recorded double-digit growth in all territories. In the U.S. and in Western Europe, sales were up 11.8% to 41 million and 13.0% to 25 million, respectively. In Emerging Markets, sales were up 29.4% to 21 million. In 2014, sales of Apidra grew 19.1% to 336 million.

Fourth-quarter and 2014 sales of Lyxumia were 8 million and 27 million, respectively.

Afrezza (a new rapid-acting inhaled insulin therapy; worldwide exclusive licensing agreement with MannKind) was launched in the U.S. at the beginning of February 2015.

*Excluding the category change: +1.4% in Q4 2014 and -4.5% in 2014

**Excluding the category change: -1.4 % in Q4 2014 and +6.0% in 2014

***Excluding the category change: +4.2 % in Q4 2014 and +6.8% in 2014

Sales of Consumer Healthcare products (CHC) were 817 million in the fourth quarter, an increase of 14.0%. Several products (amounting to 68 million in sales) previously recorded in prescription pharmaceuticals in the fourth quarter of 2013 were transferred to Consumer Healthcare products. Excluding this category change, sales of CHC grew 4.2% driven by the success of the Nasacort Rx-to-OTC switch in the U.S. and good performance of

Doliprane and Enterogermina . Sales of Nasacort Allergy 24HR nasal spray, which has been available over-the-counter (OTC) in the U.S. since February 2014, were 17 million in the fourth quarter in the U.S. In 2014, sales of CHC were 3,337 million, an increase of 16.5%. Excluding the category change mentioned above ( 273 million in 2013), CHC sales grew 6.8%.

Fourth-quarter sales of Genzyme grew 22.2% to 746 million boosted by the performance of Aubagio . Sales of Genzyme grew 28.6% to 299 million in the U.S., 16.3% to 229 million in Western Europe, 22.3% to 154 million in Emerging Markets and 17.9% to 64 million in the rest of the World. In 2014, sales of Genzyme reached 2,604 million, an increase of 24.3%.

Fourth-quarter and 2014 sales of Rare Diseases were 584 million (up 9.7%) and 2,137 million (up 11.2%), respectively.

Sales of Cerezyme increased 8.3% to 197 million in the fourth quarter, driven by strong performance in Emerging Markets (up 20.9% to 77 million). Full-year sales of Cerezyme grew 8.3% to 715 million. Sales of Cerdelga , the only first-line oral therapy for Gaucher disease type 1 patients, which was approved by the FDA in August, were 4 million. In January, the EMA also approved Cerdelga for Gaucher disease type 1 patients.

Fourth-quarter sales of Fabrazyme increased 14.4% to 123 million driven by double-digit growth in all territories. Sales of Fabrazyme grew 11.5% to 29 million in Western Europe, 12.2% to 59 million in the U.S., 26.7% to 18 million in Emerging Markets and 14.3% to 17 million in the rest of the World. Full-year sales of Fabrazyme grew 23.0% to 460 million.

Sales of Myozyme /Lumizyme grew 11.5% to 150 million in the fourth quarter, driven by the U.S. (up 25.8% to 43 million) due in part to conversion of clinical patients and Emerging Markets (up 28.6% to 27 million). Over the period, sales in Western Europe were stable at 71 million. In 2014, sales of Myozyme /Lumizyme grew 9.8% to 542 million.

Fourth-quarter and 2014 sales of Multiple Sclerosis were 162 million (up 114.1%) and 467 million (up 178.0%), respectively.

Sales of Aubagio were 146 million in the fourth quarter of 2014 versus 69 million for the same period of 2013. In the U.S., sales of Aubagio were 108 million versus 55 million in the fourth quarter of 2013. In Western Europe, where the launch of the product started in the fourth quarter of 2013, sales reached 27 million in the fourth quarter. Full-year sales of Aubagio totaled 433 million, up 160.8%.

Fourth quarter and full-year sales of Lemtrada were 16 million and 34 million, respectively. Fourth-quarter sales of the product were 12 million in Western Europe. In November, the U.S. Food and Drug Administration (FDA) approved Lemtrada for the treatment of patients with relapsing forms of multiple sclerosis. In the U.S., fourth-quarter sales of Lemtrada were 2 million.

Other Innovative Products(1)

(1) Includes new product launches which do not belong to the other Growth Platforms

Fourth-quarter sales of Other Innovative Products were 209 million, an increase of 5.9% in the fourth quarter and 815 million, an increase of 14.7% in 2014.

Fourth-quarter and 2014 sales of Multaq were 75 million (down 1.4%) and 290 million (up 7.8%), respectively. In the fourth quarter, sales of Jevtana grew 9.1% to 74 million. Full-year sales of Jevtana grew 19.5% to 273 million. Fourth-quarter and 2014 sales of Mozobil were 31 million (up 16.0%) driven by the U.S. (up 14.3% to 18 million) and 111 million (up 9.9%), respectively. In the fourth quarter, sales of Zaltrap grew 33.3% to 20 million, driven by recent launches in Western Europe which offset lower sales in the U.S. Full-year sales of the product were 69 million (up 30.2%).

Other Pharmaceutical Products

Fourth-quarter sales of Plavix increased 1.6% to 500 million, driven by Emerging Markets (up 4.2% to 233 million) and Japan (up 5.7% to 211 million). In mid-2015, generic versions of Plavix are anticipated to enter the market in Japan. In China, sales of the product increased 9.6% to 135 million. Full-year sales of Plavix increased 4.7% to 1,862 million.

Sales of Lovenox were 436 million down 0.5% in the fourth quarter due to lower sales in the U.S. (down 37.3% to 35 million) as a result of generic competition. In Emerging Markets, Lovenox continued its strong performance with sales up 10.6% to 154 million driven by China, Brazil and Russia. In Western Europe, sales of the product were 226 million (up 1.4%). In 2014, sales of Lovenox totaled 1,699 million, an increase of 2.1%.

Sales of Renvela /Renagel were 213 million in the fourth quarter, down 7.8% reflecting lower sales in the U.S. (down 11.0% to 159 million). In the U.S., sales were impacted by the agreement with Impax which was granted a license to sell a limited allotment of bottles of an authorized generic version of Renvela tablets in the U.S. beginning in April 2014. The specific allotment corresponds to up to 10% of the total 2013 sevelamer sales in the U.S. In 2014, sales of Renvela /Renagel were 684 million, a decrease of 8.7%.

In the fourth quarter, sales of Aprovel /Avapro were 177 million, down 11.9%, reflecting generic competition in Western Europe where sales decreased 35.8% to 43 million. Full-year sales of Aprovel /Avapro were 727 million, down 16.6%.

In the fourth quarter, sales of Allegra as a prescription drug were 41 million, down 50.6% (excluding the change of category, sales decreased 25.9%) and sales of the Ambien family of products were 77 million, down 26.9%, mainly reflecting generic competition in Japan for both products. Full-year sales of Allegra and the Ambien family of products were 192 million and 306 million, respectively.

Fourth-quarter and 2014 sales of Taxotere decreased 31.1% ( 71 million) and 31.5% ( 266 million), respectively, mainly due to generic erosion. Fourth-quarter and full-year 2014 sales of Eloxatin increased 34.6% ( 74 million) and decreased 2.7% ( 210 million), respectively.

Sales of Generics were down 0.6% to 467 million in the fourth quarter, reflecting lower sales in Western Europe (down 7.7% to 133 million) and the U.S. (down 25.7% to 29 million) which offset the recovery in Brazil (up 22% to 71 million ). Full-year sales of Generics grew 16.2% to 1,805 million (down 2.8% excluding Brazil generics).

In the fourth quarter, consolidated sales of Sanofi Pasteur increased 16.2% to 1,177 million reflecting strong performance of influenza vaccines in the U.S. and Emerging Markets as well as the continued recovery of Pentacel in the U.S. Fourth-quarter sales increased 22.3% (to 653 million) and 19.9% (to 441 million) in the U.S. and Emerging Markets, respectively. Full-year consolidated sales of Sanofi Pasteur grew 7.2% to 3,974 million, despite remaining capacity constraints (which Sanofi continues to address in 2015) in a context of strong demand.

Sales of Influenza vaccines grew 59.1% to 334 million in the fourth quarter as a result of Sanofi Pasteur s strategy to offer differentiated vaccines in the U.S. and strong performance in Emerging Markets. In the U.S., sales of influenza vaccines increased 65.3% to 217 million in the fourth quarter. In 2014, differentiated vaccines such as Fluzone Quadrivalent vaccine (a four-strain influenza vaccine), Fluzone High-Dose for elderly people, and Fluzone ID (which uses a novel microinjection system for intradermal delivery) represented 88% of flu vaccines sales in the U.S. (versus 41% in 2013). In the fourth quarter, sales of influenza vaccines in Emerging Markets increased 55.9% to 109 million and benefited from the strong growth in Mexico. Full-year sales of influenza vaccines increased 25.2% to 1,178 million.

Fourth-quarter sales of Polio/Pertussis/Hib vaccines increased 12.0% to 400 million. In the U.S., Polio/Pertussis/Hib vaccines sales reached 148 million, an increase of 31.4% reflecting the continuous recovery of Pentacel . In Emerging Markets sales of Polio/Pertussis/Hib vaccines grew 20.9% to 220 million sustained by higher sales of Pentaxim and the launch of Hexaxim . In China, fourth-quarter sales of Pentaxim were lower reflecting variability of supply and lower inventory level. In the rest of the world, fourth-quarter sales of Polio/Pertussis/Hib vaccines decreased 42.3% to 28 million reflecting lower sales of the Polio vaccine, Imovax , in Japan. Full-year sales of Polio/Pertussis/Hib vaccines were 1,154 million, up 1.9%.

In the fourth quarter, sales of Menactra increased 19.0% to 80 million reflecting 13.5% growth in the U.S. In 2014, sales of Menactra were 407 million down 3.1%. In the U.S. Menactra s strong market share was maintained in 2014

Sales of Adult Booster vaccines were down 1.0% to 103 million and up 2.0% to 398 million in the fourth quarter and in full-year 2014, respectively.

Sales of Travel and Other Endemic vaccines were down 9.2% to 100 million and up 1.6% to 377 million in the fourth quarter and in 2014, respectively.

Sales of Sanofi Pasteur MSD (not consolidated), the joint venture with Merck & Co. in Europe, were 240 million, (down 2.8% on a reported basis) and 848 million (down 3.3% on a reported basis) in the fourth quarter and in 2014, respectively.

Fourth-quarter sales of Animal Health increased 11.5% to 507 million sustained by the success of the NexGard launch and performance of fipronil products after a difficult 2013. In the U.S., Animal Health sales increased 35.7% to 170 million in the fourth quarter. Full-year sales of Animal Health increased 6.7% to 2,076 million.

Sales of the Companion Animals segment were up 21.5% to 275 million in the fourth-quarter, reflecting the success of the NexGard launch as well as performance of Frontline family of products (+16.0%). NexGard , Merial s next generation flea and tick product for dogs, was launched in the U.S. in the first quarter of 2014 and in most European countries during 2014. Sales of NexGard totaled 28 million in the fourth quarter and 113 million in the full year. Fourth-quarter sales of the Companion Animals segment increased 39.8% in the U.S. to 141 million and 11.7% in Western Europe to 67 million. Full-year sales of the Companion Animals segment grew 8.8% to 1,281 million.

Fourth-quarter sales of the Production Animals segment were 232 million, up 1.8%. Strong performance of the avian and swine businesses was partially offset by the negative impact of Veterinary Public Health products. (sales of Veterinary Public Health products were stable in 2014). In 2014, sales of the Production Animals segment were up 3.5% to 795 million.

Net sales by geographic region

(a) World less the U.S., Canada, Western Europe, Japan, Australia and New Zealand;

(b) France, Germany, UK, Italy, Spain, Greece, Cyprus, Malta, Belgium, Luxembourg, Portugal, Netherlands, Austria, Switzerland, Sweden, Ireland, Finland, Norway, Iceland, Denmark;

(c) Japan, Canada, Australia and New Zealand

Fourth-quarter sales in Emerging Markets were up 7.9% to 3,126 million. Pharmaceuticals sales increased 6.2% driven by Diabetes (up 17.3%) and Genzyme (up 22.3%). Sales in China were 439 million, up 1.8%, Pharmaceuticals performance (up 12.4%) was partially offset by lower sales of Pentaxim . In China, the Pharmaceuticals sales growth was driven by Plavix and Lantus . Fourth-quarter sales in Eastern Europe, Russia

and Turkey increased 5.8% to 673 million supported by good performance in Turkey and Hungary. In Eastern Europe fourth-quarter sales were 345 million (up 3.4%). Sales in Russia reached 208 million, up 6.4% driven by Diabetes. In Africa and Middle-East, sales grew 3.5% to 596 million. In Brazil, sales were 318 million, down 3.3%. Full-year sales in Emerging Markets were up 9.3% to 11,347 million. Excluding Brazil generics, 2014 sales in Emerging Markets grew 6.5%. In 2014, sales in China were 1,603 million (up 8.8%), sales in Brazil were 1,382 million (up 34.8% or 6.9% excluding generics) and sales in Russia were 813 million (up 7.1%).

In the U.S., sales increased 8.8% to 3,147 million in the fourth quarter, due to performance of Genzyme (up 28.6%), Vaccines (up 22.3%), Diabetes (up 10.2%) and Animal Health (up 35.7%). Full-year sales in the U.S. grew 8.2% to 11,339 million.

Fourth-quarter sales in Western Europe were 1,956 million (up 0.1%). The performance of Genzyme (up 16.3%) and Diabetes (up 10.0%) were offset by the impact of generic competition to Aprovel . In 2014, sales in Western Europe were stable at 7,865 million.